02816nam 2200673Ia 450 99621730510331620240410133942.01-280-01137-897866100113770-585-49272-792-4-068153-1(CKB)1000000000008536(EBL)284791(OCoLC)191039474(SSID)ssj0000271404(PQKBManifestationID)11253775(PQKBTitleCode)TC0000271404(PQKBWorkID)10295697(PQKB)11709562(MiAaPQ)EBC284791(Au-PeEL)EBL284791(CaPaEBR)ebr10047391(CaONFJC)MIL1137(OCoLC)55664162(EXLCZ)99100000000000853620040211d2003 my 0engur|n|---|||||txtccrWHO Expert Committee on Drug Dependence[electronic resource] thirty-third report1st ed.Geneva World Health Organization20031 online resource (31 p.)WHO technical report series ;915Description based upon print version of record.92-4-120915-1 Contents; 1. Introduction; 2. Scheduling criteria; 3. Critical review of psychoactive substances; 4. Pre-review of psychoactive substances; 5. Terminology used in reporting abuse-related adverse drug reactions; 6. Other matters; Acknowledgements; References; Annex Terminology used in reporting abuse-related adverse drug reactions; References;This report presents the recommendations of a WHO Expert Committee responsible for reviewing information on dependence-producing drugs to assess the need for their international control. The first part of the report contains a summary of the Committee's evaluations of seven substances (dronabinol, oripavine, buprenorphine, butorphanol, ketamine, khat and zopiclone). The report also discusses the substances that were pre-reviewed (gamma-hydroxybutyric acid and tramadol) and recommended gamma-hydroxybutyric acid for critical review at a future meeting. Two substances (gamma-butyrolactone and 1,4Technical report series (World Heald Organization) ;915.Substance abuseDrug abuseDesigner drugsStereoisomersEphedrineSubstance abuse.Drug abuse.Designer drugs.Stereoisomers.Ephedrine.362.29MiAaPQMiAaPQMiAaPQBOOK996217305103316WHO Expert Committee on Drug Dependence2025022UNISA